RAJAF — Cordyceps Sunshine Biotech Holdings Co Balance Sheet
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMid Cap
- $1.02bn
- $1.02bn
- $1.25m
Annual balance sheet for Cordyceps Sunshine Biotech Holdings Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0 | 0.1 | 0.007 | 0.023 | 0.037 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.244 | 0.511 | 0.009 | — | 0 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.949 | 1.12 | 0.502 | 0.327 | 0.602 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.73 | 1.99 | 0.254 | 3.01 | 4.01 |
| Other Long Term Assets | |||||
| Total Assets | 2.83 | 3.25 | 2.1 | 3.35 | 4.62 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.41 | 2.91 | 2.52 | 2.97 | 4.99 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.84 | 3.53 | 3.06 | 3.5 | 5 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -0.013 | -0.276 | -0.951 | -0.152 | -0.376 |
| Total Liabilities & Shareholders' Equity | 2.83 | 3.25 | 2.1 | 3.35 | 4.62 |
| Total Common Shares Outstanding |